Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02580305 · ClinicalTrials.gov registry record · Phase 2
SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study
A Phase 2 study, sponsored by Suven Life Sciences Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 564
- Enrollment target
NCT02580305: Completed Phase 2 study, sponsored by Suven Life Sciences Limited.
NCT02580305 is a Phase 2 study that has completed, run by Suven Life Sciences Limited. The registered enrollment target is 564 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (324% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02580305, a Phase 2 study, has completed, sponsored by Suven Life Sciences Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 564 participants
- Enrollment target
Study Summary
This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving stable doses of donepezil HCl and memantine HCl.
Primary Outcome
Mean change from baseline at week 26 is assessed for ADAS-Cog11 score. The ADAS-Cog11 is a structured scale that evaluates memory, orientation, attention, reasoning, language, and constructional praxis. ADAS-Cog11 measures cognition by assessing 11 metrics impaired in AD: word recall; commands; constructional praxis; naming objects and fingers; ideational praxis; orientation; word recognition; remembering test instructions; spoken language ability; word-finding difficulty; and comprehension of s
Interventions
- DRUG Placebo
- DRUG Memantine
- DRUG Donepezil
- DRUG SUVN-502
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 564 participants |
| Start Date | 2015-09 |
| Est. Completion | 2019-11-07 |
| Phase | Phase 2 |
What the finished NCT02580305 record still lists
NCT02580305 is an interventional study that assigns participants to a tested intervention. The registered 564 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (324% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02580305 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02580305 about?
NCT02580305 is a clinical study titled "SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study". This is a phase 2a, proof-of-concept, 26-week, double-blind, multicenter, randomized, parallel group, placebo-controlled study to compare the efficacy and safety of treatment with SUVN-502 to placebo treatment in subjects with moderate Alzheimer's disease receiving stable doses of donepezil HCl and ...
What is the current status of trial NCT02580305?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 564 participants. The study started on 2015-09. Estimated completion is 2019-11-07.
What interventions are being tested in trial NCT02580305?
The interventions under investigation include: Placebo (DRUG), Memantine (DRUG), Donepezil (DRUG), SUVN-502 (DRUG).
Who is sponsoring clinical trial NCT02580305?
This trial is sponsored by Suven Life Sciences Limited, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02580305's enrollment target sits among peer trials
564 60th of 2000 higher than 1,941 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06146725 · 564 participants
The RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)
- NCT06188520 · 564 participants · Phase 1
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
- NCT06628453 · 564 participants · NA
CGM for Management of Type 2 Diabetes in Pregnancy
- NCT07125326 · 564 participants · NA
How the Method of Bladder Emptying After Epidural Placement in Labor Affects Postpartum Voiding
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia